Author: admin

Prime Care VIP: NP2ME Unveils New Brand Name and Reinforces Commitment to Affordable Mobile Concierge Primary Medical Care

“Prime Care VIP is “Primary Care Delivered” – Affordable and Convenient House Call Family Medicine”

May 13, 2024 – NP2ME, a recognized leader in innovative healthcare solutions, has announced the completion of a significant rebranding to reflect the company’s evolution and renewed mission. Effective on March 19, 2024, the company now operates under the new name, Prime Care VIP. This change underscores the organization’s continued commitment to delivering high-quality, concierge primary medical care at an affordable price.

Prime Care VIP is a pioneer and disrupter in the Direct Primary Care movement, which is rapidly becoming the fastest-growing segment within the healthcare industry. By focusing its efforts on this new care model, Prime Care VIP eliminates the complexity of traditional health insurance, offering patients direct access to their healthcare providers for a flat and affordable monthly fee. This approach not only enhances the patient-provider relationship but also dramatically reduces overhead costs and increases healthcare efficiency which the patient experiences an immediate benefit from in time and cost savings.

“Prime Care VIP represents a natural progression for our brand as we expand our services and refine our focus on personalized health care that is both accessible and affordable,” said Michael Kieffer, CEO of Prime Care VIP. “Our new identity as Prime Care VIP better communicates our core values and our promise to deliver a healthcare experience that prioritizes the patient’s primary care needs without the financial burden typically associated with high-caliber medical care.”

Prime Care VIP’s rebranding includes a new visual identity, logo, and website. Patients and prospective clients can now visit www.primecarevip.com to learn more about the services offered, membership benefits, and the future of healthcare through Prime Care VIP.

About Prime Care VIP 

Prime Care VIP is a pioneering healthcare provider specializing in mobile concierge primary medical care. With a focus on the Direct Primary Care model, Prime Care VIP aims to revolutionize the healthcare landscape by making quality care more affordable, directly accessible, and providing better pricing and access to ancillary services. Additionally, as a mobile service that provides house calls, Prime Care VIP offers unparalleled convenience by delivering medical care right to your doorstep, further personalizing the healthcare experience. Prime Care VIP is dedicated to building long-term relationships with patients and businesses, providing comprehensive care that goes beyond episodic treatment, and fostering a healthcare environment that prioritizes the well-being and financial health of its community.

For further information, please contact:

Michael Kieffer 

CEO
Prime Care VIP
Email: info@primecarevip.com
Phone: 561-948-2020
Website: [www.primecarevip.com] (http://www.primecarevip.com)

Media Contact
Company Name: Prime Care VIP
Contact Person: Michael Kieffer
Email: Send Email
Phone: 561-948-2020
Address:10055 Yamato Rd Ste 115
City: Boca Raton
State: Florida
Country: United States
Website: www.primecarevip.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Prime Care VIP: NP2ME Unveils New Brand Name and Reinforces Commitment to Affordable Mobile Concierge Primary Medical Care

Multiple Sclerosis Pipeline Assessment, 2024 Updates: FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, and Growth Prospects | Celgene, Actelion, Bayer, Acorda

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Multiple Sclerosis pipeline constitutes 100+ key companies continuously working towards developing 100+ Multiple Sclerosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Multiple Sclerosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

“Multiple Sclerosis Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Multiple Sclerosis Market. 

 

Some of the key takeaways from the Multiple Sclerosis Pipeline Report: 

  • Companies across the globe are diligently working toward developing novel Multiple Sclerosis treatment therapies with a considerable amount of success over the years. 

  • Multiple Sclerosis companies working in the treatment market are Gossamer Bio, 4D Pharma, HuniLife Biotechnology, Anokion, GSK plc, ImCyse, Ever Supreme Bio Technology, Sanofi, RemeGen, GeNeuro, Immunic Therapeutics, Sanofi, Hoffman-La-Roche, and others, are developing therapies for the Multiple Sclerosis treatment 

  • Emerging Multiple Sclerosis therapies in the different phases of clinical trials are- GB7208, MRx0002, HuL001, ANK-700, GSK3888130, IMCY-0141, UMSC-01, SAR443820, RC18, Temelimab, IMU-838, Tolebrutinib, Fenebrutinib, and others are expected to have a significant impact on the Multiple Sclerosis market in the coming years. 

  • In January 2024, Atara Biotherapeutics announced that its Phase II EMBOLD clinical trial evaluating ATA188 for non-active progressive multiple sclerosis (PMS) did not achieve the primary endpoint. The trial, which was double-blind, open-label extension, placebo-controlled, and randomized, aimed to evaluate the effectiveness and safety of ATA188 in patients with non-active PMS. Initial assessment results at 12 months showed that the trial did not meet the primary endpoint of confirmed disability improvement (CDI) based on the expanded disability status scale (EDSS) compared to placebo.  

  • In January 2022, Immunic Therapeutics has commenced a multicenter clinical trial that includes a randomized, double-blind, placebo-controlled investigation. This study consists of both a blinded Main Treatment Period (MT) and an Open Label Period (OLE), aiming to assess the effectiveness, safety, and tolerance of IMU-838 in adult patients diagnosed with relapsing multiple sclerosis (RMS).

  • In June 2022, Immunic revealed additional supportive findings from its phase II EMPhASIS trial of the vidofludimus calcium formulation. The results indicated decreases in MRI lesions among patients diagnosed with relapsing multiple sclerosis (MS), coupled with a positive safety profile.

 

Multiple Sclerosis Overview

The most prevalent neurological condition affecting young adults is multiple sclerosis (MS), which often manifests as symptoms between the ages of 20 and 40. Myelin, also referred to as white matter, protects the central nervous system’s axons from damage in multiple sclerosis (MS).About 85% of MS patients have relapsing-remitting MS, which is the most prevalent type.

 

Get a Free Sample PDF Report to know more about Multiple Sclerosis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/multiple-sclerosis-pipeline-insight

 

Emerging Multiple Sclerosis Drugs Under Different Phases of Clinical Development Include:

  • GB7208: Gossamer Bio

  • MRx0002: 4D Pharma

  • HuL001: HuniLife Biotechnology

  • ANK-700: Anokion

  • GSK3888130: GSK plc

  • IMCY-0141: ImCyse

  • UMSC-01: Ever Supreme Bio Technology

  • SAR443820: Sanofi

  • RC18: RemeGen

  • Temelimab: GeNeuro

  • IMU-838: Immunic Therapeutics

  • Tolebrutinib: Sanofi

  • Fenebrutinib: Hoffman-La-Roche

 

Multiple Sclerosis Route of Administration

Multiple Sclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral

  • Parenteral

  • Intravenous

  • Subcutaneous

  • Topical.

  • Molecule Type

 

Multiple Sclerosis Molecule Type

Multiple Sclerosis Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy

  • Product Type

 

Multiple Sclerosis Pipeline Therapeutics Assessment

  • Multiple Sclerosis Assessment by Product Type

  • Multiple Sclerosis By Stage and Product Type

  • Multiple Sclerosis Assessment by Route of Administration

  • Multiple Sclerosis By Stage and Route of Administration

  • Multiple Sclerosis Assessment by Molecule Type

  • Multiple Sclerosis by Stage and Molecule Type

 

DelveInsight’s Multiple Sclerosis Report covers around 5+ products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I)

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration

 

Further Multiple Sclerosis product details are provided in the report. Download the Multiple Sclerosis pipeline report to learn more about the emerging Multiple Sclerosis therapies

 

Some of the key companies in the Multiple Sclerosis Therapeutics Market include:

Key companies developing therapies for Multiple Sclerosis are – Celgene, Actelion (now Janssen Pulmonary Hypertension), EMD Serono, Inc., Bayer, Acorda Therapeutics, Inc., Biogen, Teva Pharmaceuticals, Novartis, Sanofi, F. Hoffmann-La Roche Ltd, and others.

 

Multiple Sclerosis Pipeline Analysis:

The Multiple Sclerosis pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Multiple Sclerosis with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Multiple Sclerosis Treatment.

  • Multiple Sclerosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Multiple Sclerosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Multiple Sclerosis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Multiple Sclerosis drugs and therapies

 

Multiple Sclerosis Pipeline Market Drivers

  • Increasing Population with Multiple Sclerosis, extensive Approved therapies, wide range of R&D Pipeline, increasing Awareness are some of the important factors that are fueling the Multiple Sclerosis Market.

 

Multiple Sclerosis Pipeline Market Barriers

  • However, high cost of drugs, high Incidence of adverse events and other factors are creating obstacles in the Multiple Sclerosis Market growth.

 

Scope of Multiple Sclerosis Pipeline Drug Insight    

  • Coverage: Global

  • Key Multiple Sclerosis Companies: Gossamer Bio, 4D Pharma, HuniLife Biotechnology, Anokion, GSK plc, ImCyse, Ever Supreme Bio Technology, Sanofi, RemeGen, GeNeuro, Immunic Therapeutics, Sanofi, Hoffman-La-Roche, and others

  • Key Multiple Sclerosis Therapies: GB7208, MRx0002, HuL001, ANK-700, GSK3888130, IMCY-0141, UMSC-01, SAR443820, RC18, Temelimab, IMU-838, Tolebrutinib, Fenebrutinib, and others

  • Multiple Sclerosis Therapeutic Assessment: Multiple Sclerosis current marketed and Multiple Sclerosis emerging therapies

  • Multiple Sclerosis Market Dynamics: Multiple Sclerosis market drivers and Multiple Sclerosis market barriers 

 

Request for Sample PDF Report for Multiple Sclerosis Pipeline Assessment and clinical trials

 

Table of Contents

1. Multiple Sclerosis Report Introduction

2. Multiple Sclerosis Executive Summary

3. Multiple Sclerosis Overview

4. Multiple Sclerosis- Analytical Perspective In-depth Commercial Assessment

5. Multiple Sclerosis Pipeline Therapeutics

6. Multiple Sclerosis Late Stage Products (Phase II/III)

7. Multiple Sclerosis Mid Stage Products (Phase II)

8. Multiple Sclerosis Early Stage Products (Phase I)

9. Multiple Sclerosis Preclinical Stage Products

10. Multiple Sclerosis Therapeutics Assessment

11. Multiple Sclerosis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Multiple Sclerosis Key Companies

14. Multiple Sclerosis Key Products

15. Multiple Sclerosis Unmet Needs

16 . Multiple Sclerosis Market Drivers and Barriers

17. Multiple Sclerosis Future Perspectives and Conclusion

18. Multiple Sclerosis Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight

 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Multiple Sclerosis Pipeline Assessment, 2024 Updates: FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, and Growth Prospects | Celgene, Actelion, Bayer, Acorda

Type 2 Diabetes Pipeline Drugs Analysis Report, 2024: FDA Approvals, Clinical Trials, Therapies, MAO, ROA by DelveInsight | Melior Pharma, Adocia, Pfizer, Ionis Pharma, Eli Lilly, Oramed Pharma

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Type 2 Diabetes pipeline constitutes 100+ key companies continuously working towards developing 100+ Type 2 Diabetes treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Type 2 Diabetes Pipeline report provides a thorough commercial and clinical evaluation of pipeline products, spanning from pre-clinical development to market availability. It includes a comprehensive overview of each drug, encompassing its mechanism of action, clinical studies, potential NDA approvals, and various product development aspects such as technology, collaborations, mergers, acquisitions, funding, designations, and other pertinent details.

 

“Type 2 Diabetes Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Type 2 Diabetes Market.

 

Some of the key takeaways from the Type 2 Diabetes Pipeline Report: 

  • Companies across the globe are diligently working toward developing novel Type 2 Diabetes treatment therapies with a considerable amount of success over the years. 

  • Type 2 Diabetes companies working in the treatment market are Abarceo Pharma, Carmot Therapeutics, Neurodon, Eccogene, Suzhou Alphamab Co., Ltd., Sciwind Biosciences, Amgen, Regor Pharmaceuticals, Jiangsu Hengrui Medicine Co, Celon Pharma, Oramed Pharmaceuticals, Eli Lilly and Company, Novo Nordisk, and others, are developing therapies for the Type 2 Diabetes treatment 

  • Emerging Type 2 Diabetes therapies in the different phases of clinical trials are- Research programme-type 2 diabetes mellitus therapeutics, CT996, NRDN-101, ECC5004, KN056, XW014, AMG 133, RGT001-075, HR17031, CPL207280, ORMD-0801, LY-3209590, Insulin icodec, and others are expected to have a significant impact on the Type 2 Diabetes market in the coming years.   

  • In June 2023, Pfizer Inc. declared its intention to advance a specific oral late-stage glucagon-like peptide-1 receptor agonist (GLP-1-RA) candidate further into clinical development for potential use in treating adults with obesity and Type 2 diabetes mellitus (T2DM). The company will proceed with advancing the clinical program for danuglipron (PF-06882961), contingent upon the outcomes from the ongoing Phase 2 trial.

  • In January 2023, Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical enterprise concentrating on oral drug delivery systems, revealed key findings from its Phase III randomized, double-blind, placebo-controlled, multicenter clinical trial (ORA-D-013-1) assessing the effectiveness of ORMD-0801 compared to placebo in individuals with Type 2 Diabetes (T2D) over a 26-week period.

 

Type 2 Diabetes Overview

Diabetes is a long-term metabolic disorder marked by fluctuations in blood glucose (blood sugar) levels. Over time, diabetes can cause serious harm to the heart, blood vessels, eyes, kidneys, nerves, and blood vessels.

 

Get a Free Sample PDF Report to know more about Type 2 Diabetes Pipeline Therapeutic Assessment- 

https://www.delveinsight.com/report-store/type-2-diabetes-pipeline-insight

 

Emerging Type 2 Diabetes Drugs Under Different Phases of Clinical Development Include:

  • Research programme: type 2 diabetes mellitus therapeutics Abarceo Pharma

  • NRDN-101: Neurodon

  • ECC5004: Eccogene

  • KN056: Suzhou Alphamab Co., Ltd. 

  • XW014: Sciwind Biosciences

  • RGT001-075: Regor Pharmaceuticals

  • HR17031: Jiangsu Hengrui Medicine Co.

  • CPL207280: Celon Pharma

  • THDB0206: Tonghua Dongbao Pharmaceutical

  • LY-3209590: Eli Lilly and Company

  • Insulin icodec: Novo Nordisk

  • ECC5004: Eccogene

  • KN056: Suzhou Alphamab Co., Ltd.

  • XW014: Sciwind Biosciences

  • AMG 133: Amgen

  • RGT001-075: Regor Pharmaceuticals

  • HR17031: Jiangsu Hengrui Medicine Co

  • CPL207280: Celon Pharma

  • CT996: Carmot Therapeutics

  • NRDN-101: Neurodon

  • ORMD-0801: Oramed Pharmaceuticals

  • LY-3209590: Eli Lilly and Company

  • Insulin icodec: Novo Nordisk

 

Type 2 Diabetes Route of Administration

Type 2 Diabetes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Intra-articular

  • Intraocular

  • Intrathecal

  • Intravenous

  • Ophthalmic

  • Oral

  • Parenteral

  • Subcutaneous

  • Topical

  • Transdermal

  • Molecule Type

 

Type 2 Diabetes Molecule Type

Type 2 Diabetes Products have been categorized under various Molecule types, such as

  • Oligonucleotide

  • Peptide

  • Small molecule

  • Product Type

 

Type 2 Diabetes Pipeline Therapeutics Assessment

  • Type 2 Diabetes Assessment by Product Type

  • Type 2 Diabetes By Stage and Product Type

  • Type 2 Diabetes Assessment by Route of Administration

  • Type 2 Diabetes By Stage and Route of Administration

  • Type 2 Diabetes Assessment by Molecule Type

  • Type 2 Diabetes by Stage and Molecule Type

 

DelveInsight’s Type 2 Diabetes Report covers around 100+ products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I)

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration

 

Further Type 2 Diabetes product details are provided in the report. Download the Type 2 Diabetes pipeline report to learn more about the emerging Type 2 Diabetes therapies

 

Some of the key companies in the Type 2 Diabetes Therapeutics Market include:

Key companies developing therapies for Type 2 Diabetes are – Novo Nordisk, Jiangsu Hengrui Medicine, Melior Pharmaceuticals, Adocia, Pfizer, AgeX Therapeutics, CarmotTherapeutics, Genexine, Inc., OPKO Health, Inc., VitNovo, Inc., Sciwind Biosciences, Caelus Health, SCOHIA PHARMA, Ionis Pharmaceuticals, Eli Lilly and Company, Oramed Pharmaceuticals, AstraZeneca, Aerami Therapeutics, Viking Therapeutics, VTV Therapeutics, AptamiR Therapeutics, Avolynt, Inc., Suzhou Yabao Pharmaceutical, CONJUCHEM, LLC., Hua Medicine, REMD Biotherapeutics, Novmeta Pharma, Afimmune Limited,  Xeris Pharmaceuticals, Akros Pharma Inc., and others.

 

Type 2 Diabetes Pipeline Analysis:

The Type 2 Diabetes pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Type 2 Diabetes with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Type 2 Diabetes Treatment.

  • Type 2 Diabetes key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Type 2 Diabetes Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Type 2 Diabetes market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Type 2 Diabetes drugs and therapies

 

Type 2 Diabetes Pipeline Market Drivers

  • Increasing Prevalence, government bodies are collaborating with major market players for the launch of new products, increase in the demand for insulin over the world are some of the important factors that are fueling the Type 2 Diabetes Market.

 

Type 2 Diabetes Pipeline Market Barriers

  • However, side-effects associated with the treatment of Type 2 Diabetes, a lack of knowledge about a healthy diet, medication initiation and other factors are creating obstacles in the Type 2 Diabetes Market growth.

 

Scope of Type 2 Diabetes Pipeline Drug Insight    

  • Coverage: Global

  • Key Type 2 Diabetes Companies: Abarceo Pharma, Carmot Therapeutics, Neurodon, Eccogene, Suzhou Alphamab Co., Ltd., Sciwind Biosciences, Amgen, Regor Pharmaceuticals, Jiangsu Hengrui Medicine Co, Celon Pharma, Oramed Pharmaceuticals, Eli Lilly and Company, Novo Nordisk, and others

  • Key Type 2 Diabetes Therapies: Research programme-type 2 diabetes mellitus therapeutics, CT996, NRDN-101, ECC5004, KN056, XW014, AMG 133, RGT001-075, HR17031, CPL207280, ORMD-0801, LY-3209590, Insulin icodec, and others

  • Type 2 Diabetes Therapeutic Assessment: Type 2 Diabetes current marketed and Type 2 Diabetes emerging therapies

  • Type 2 Diabetes Market Dynamics: Type 2 Diabetes market drivers and Type 2 Diabetes market barriers 

 

Request for Sample PDF Report for Type 2 Diabetes Pipeline Assessment and clinical trials

 

Table of Contents

1. Type 2 Diabetes Report Introduction

2. Type 2 Diabetes Executive Summary

3. Type 2 Diabetes Overview

4. Type 2 Diabetes- Analytical Perspective In-depth Commercial Assessment

5. Type 2 Diabetes Pipeline Therapeutics

6. Type 2 Diabetes Late Stage Products (Phase II/III)

7. Type 2 Diabetes Mid Stage Products (Phase II)

8. Type 2 Diabetes Early Stage Products (Phase I)

9. Type 2 Diabetes Preclinical Stage Products

10. Type 2 Diabetes Therapeutics Assessment

11. Type 2 Diabetes Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Type 2 Diabetes Key Companies

14. Type 2 Diabetes Key Products

15. Type 2 Diabetes Unmet Needs

16 . Type 2 Diabetes Market Drivers and Barriers

17. Type 2 Diabetes Future Perspectives and Conclusion

18. Type 2 Diabetes Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Type 2 Diabetes Pipeline Drugs Analysis Report, 2024: FDA Approvals, Clinical Trials, Therapies, MAO, ROA by DelveInsight | Melior Pharma, Adocia, Pfizer, Ionis Pharma, Eli Lilly, Oramed Pharma

The Gym On Fennell and The Gym On Locke Win the 2024 Quality Business Award for The Best Gym in Hamilton, Ontario

“Company Logo”
The Gym On Fennell and The Gym On Locke are honored with the 2024 Quality Business Award for being the top gyms in Hamilton, Ontario, showcasing excellence in fitness services and facilities.

Hamilton, Ontario – May 13, 2024 – The Gym On Fennell and The Gym On Locke, are both boutique gyms that have received the 2024 Quality Business Award for The Best Gym in Hamilton, Ontario. This accolade acknowledges The Gym On Fennell and The Gym On Locke for their exceptional customer service, high-quality services, and overall business performance.

The Quality Business Awards annually acknowledges businesses exhibiting excellence within their industry. Selections are determined by taking into account their reputation, feedback from customers, and overall performance within their respective industries.

The Gym On Fennell and The Gym On Locke are exceptional gyms in Hamilton, Ontario. Stefan Witt has been a part of the health and fitness for over thirty years. In 2009, Witt was inspired to open The Gym On Locke because he wanted to create a friendly, neighbourhood gym that focuses on providing an excellent member experience. Then in 2017, Witt partnered with Pete Relewicz to open The Gym On Fennell. Both of the gym locations are locally owned and operated. They offer a boutique gym experience with top of the line exercise equipment in a clean, aesthetically pleasing loft-style facility. The two gyms have incredible staff that are highly motivated to help the members achieve their health and fitness goals. The Gym On Fennell is a large 8,100 square foot facility that also includes a wellness centre and hydro massage beds. The Gym On Fennell and The Gym On Locke are proud to serve gym goers in Hamilton.

When the time came to choose this year’s recipient, The Gym On Fennell and The Gym On Locke both emerged as noteworthy gyms in Hamilton. Their approachable, experienced team is well-regarded within the fitness community, and positive reviews of both The Gym On Fennell and The Gym On Locke are abundant. Here are a few of the numerous positive testimonials penned by satisfied individuals who were thoroughly impressed with the services and gym environments offered by The Gym On Fennell and The Gym On Locke. “I very highly recommend the Gym on Locke to anyone considering joining. It is one of the best gyms I have set foot in. The atmosphere is fantastic, the people are friendly, and the equipment is well maintained. It is a true community gym where all ages and fitness levels are welcome.“ “Very nice gym. Staff is great and very friendly. The gym clean and well kept, the interior is ascetically very nice, the equipment is all good quality. Good accommodations to keep your possessions safely locked away during workout, good shower and bathroom facilities. 24 Hour access with electronic card so you can go whenever you want. Highly recommend.“ “Always a positive experience at this gym! The staff are so kind and helpful, the facilities are always clean and I have never felt judged or uncomfortable here. The cost per month is absolutely worth it!!“ “Gym culture here is genuinely positive and open. No judgment, no influencers. Facility and equipment are always spotless and plenty of parking space throughout the day. Busiest time of day is still much quieter than other gyms with very little wait time. If you’re gym-shy and want to workout in a comfortable environment, I highly recommend Gym on Fennell.“ The entire The Gym On Fennell and The Gym On Locke teams consistently exceed expectations to those working out at their gyms in Hamilton.

The Quality Business Awards recognizes businesses achieving an average quality score of 95% or higher throughout the preceding year. To be eligible, a business must garner outstanding customer reviews from at least three different platforms. Those upholding sterling reputations and track records over multiple years with minimal complaints receive high scores. Moreover, businesses that consistently engage with and respond to customer feedback are held in high esteem. Additionally, adherence to integrity, community involvement, and proactive efforts to reduce environmental impact are important criteria. Receiving a Quality Business Award shows a dedication to delivering superior products and exceptional customer service.

For more information about The Gym On Fennell and The Gym On Locke, please visit their websites at [www.getyourgymon247.com].

Contact:

Quality Business Awards

support@qualitybusinessawards.ca

Media Contact
Company Name: The Gym On Fennell and The Gym On Locke
Contact Person: Sean Everingham
Email: Send Email
Country: Canada
Website: https://getyourgymon247.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: The Gym On Fennell and The Gym On Locke Win the 2024 Quality Business Award for The Best Gym in Hamilton, Ontario

Fred Astaire Dance Studios Wins the 2024 Quality Business Award for The Best Dance Studio in Hamilton, Ontario

“Fred Astaire Logo”
Fred Astaire Dance Studios in Hamilton, Ontario, wins the 2024 Quality Business Award for being recognized as the best dance studio in the region. Their exceptional dance programs and services have earned them this prestigious accolade.

Hamilton, Ontario – May 13, 2024 – Fred Astaire Dance Studios, a prominent dance company, serving Hamilton and surrounding communities, has received the 2024 Quality Business Award for The Best Dance Studio in Hamilton, Ontario. This accolade acknowledges Fred Astaire Dance Studios for its exceptional customer service, high-quality services, and overall business performance. The Quality Business Awards annually acknowledges businesses exhibiting excellence within their industry. Selections are determined by consideration of their reputation, feedback from customers, and overall performance within their respective industries. To qualify businesses must achieve an average quality score of 95% or higher throughout the preceding year. In addition, a business must garner outstanding customer reviews from at least three different platforms. Those upholding sterling reputations and track records over multiple years with minimal complaints receive high scores. Moreover, businesses that consistently engage with and respond to customer feedback are held in high esteem. Furthermore, adherence to integrity, community involvement, and proactive efforts to reduce environmental impact are important criteria. Receiving a Quality Business Award shows a dedication to delivering superior products and exceptional customer service.

The dance instructors at Fred Astaire Dance Studios Hamilton are both well trained and passionate about teaching and understand that people come to learn for a variety of reasons, far more meaningful than just keeping a beat. The level of excitement one experiences on the dance floor is often superseded by the sense of fun, increased social confidence, as well as an improved range of motion and flexibility, and heart health, as dancing has proven to be only second to swimming lessons in terms of cardiac fitness. In an era where many have become stuck in a sedentary lifestyle, attached to their phones, and dependent on social media to pass the time, the students who attend Fred Astaire Dance Studios not only experience it as a recreational outlet, but gain social confidence as they have the benefit of weekly group lessons and practice parties, which provide them the opportunity to meet new people and experience a sense of camaraderie, all while learning a variety of Latin and Ballroom dance styles. These include, but are not limited to: Waltz, Foxtrot, Tango, Quickstep, Cha Cha, Swing, Rumba, Samba, Mambo, Merengue and Paso Doble.

When the time came to choose this year’s recipient, Fred Astaire Dance Studios emerged as a noteworthy company in the dance sector. Their talented team of instructors are well regarded within the Hamilton dance community and online testimonials of the studio abound. It appears, as the reviews below seem to exemplify, that the staff at Fred Astaire Dance Studios Hamilton is a team consistently helping dancers to advance their dancing skills in a fun, supportive, and vibrant dance environment. 

“We joined the Fred Astaire Dance Studio in July 2023 to prepare us for our first dance at our wedding in October 2023. The instructors were truly amazing and taught us so much in that time, which left our guests amazed. The entire dance studio is always filled with positive energy and coming to our weekly dance lesson and group lesson is something I always look forward to each week (as we have continued with our dance lessons even after our wedding). I would highly recommend any couples that want to learn to dance for their wedding or even as a hobby to join the Fred Astaire Dance Studios!“ 

“All the staff are friendly and welcoming. Our instructor Michel is so helpful and praises all our successes. This is a great couples experience! We’re just getting started and are excited to experience more of what this wonderful community has to offer. We highly recommend Fred Astaire in West Hamilton! The instructors are really welcoming. They ease you into dancing and help you feel as though you know what you are doing right from the beginning. 

“My husband and I have only been taking lessons for a very short time but what a time it has been. We love it! Our instructor is amazing! So full of energy and is so encouraging. We would highly recommend this studio to anyone wanting to learn to dance.”

UPDATE: I would like to add that, after dancing for a year now, we are even more excited to be part of this amazing family! If you want to learn from the best, this is THE studio for you!”

For more information about Fred Astaire Dance Studios, please visit the company’s website at [www.fredastaire.ca]. 

Contact:

Quality Business Awards 

support@qualitybusinessawards.ca

Media Contact
Company Name: Fred Astaire Dance Studio
Email: Send Email
Phone: 1-888-973-2623
Country: Canada
Website: http://www.fredastaire.ca/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Fred Astaire Dance Studios Wins the 2024 Quality Business Award for The Best Dance Studio in Hamilton, Ontario

KRAS Inhibitors Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2023-2032), Analyzes DelveInsight | Novartis, Verastem Oncology, Boehringer Ingelheim, Roche, Eli Lilly

The KRAS Inhibitors Market Forecast report offers an in-depth understanding of the KRAS Inhibitors, historical and forecasted epidemiology as well as the KRAS Inhibitors market trends in the 7MM.

DelveInsight’s “KRAS Inhibitors Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the KRAS Inhibitors, historical and forecasted epidemiology as well as the KRAS Inhibitors market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the KRAS Inhibitors market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; KRAS Inhibitors Market Forecast

 

Some of the key facts of the KRAS Inhibitors Market Report: 

  • The KRAS Inhibitors market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

  • In February 2024, Bristol Myers Squibb reported that the US FDA has granted priority review status to the supplemental New Drug Application (sNDA) for KRAZATI in combination with cetuximab for the treatment of KRASG12C-mutated locally advanced or metastatic colorectal cancer (CRC). The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024.

  • In January 2024, The European Commission provided conditional approval for KRAZATI to treat advanced non-small cell lung cancer (NSCLC) with KRASG12C mutation, specifically for patients who have experienced disease progression after receiving at least one previous systemic therapy.

  • As per NICE (2022), the KRAS oncogene stands out as the frequently mutated gene in lung cancer. Specifically, the KRAS G12C mutation prevails as the most common, found in approximately 12% of non-small cell lung cancer (NSCLC) tumors in the UK.

  • According to research published in the American Society of Clinical Oncology (ASCO) by Salem et al. (2022), the most common KRAS variants among all subtypes were G12D (41.8%), G12V (31.6%), G12C (1.8%), G13D (0.4%), and G12R (161%). Notably, KRASG12D was predominantly found in patients diagnosed with pancreatic cancer.

  • In the chosen cancer types, Colorectal Cancer has the highest number of KRAS mutant cases, with Pancreatic Cancer and NSCLC following closely. According to the analysis, in the seven major markets (7MM), there were an estimated 216,000 cases of KRAS mutant colorectal cancer in 2023.

  • In December 2022, For adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, and who have had at least one prior systemic therapy, the FDA has given accelerated approval for KRAZATI (adagrasib), a targeted treatment option.In May 2022, Mirati filed a Marketing Authorization Application (MAA) with the EU.

  • Key KRAS Inhibitors Companies: Novartis, Verastem Oncology, Boehringer Ingelheim, Roche, Eli Lilly, Revolution Medicines, and others

  • Key KRAS Inhibitors Therapies: JDQ443, Avutometinib, BI 1701963, GDC-6036, LY353798, RMC-4630, and others

  • The KRAS Inhibitors market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage KRAS Inhibitors pipeline products will significantly revolutionize the KRAS Inhibitors market dynamics.

 

KRAS Inhibitors Overview

KRAS inhibitors are a class of drugs designed to target and block the activity of the KRAS protein, which plays a key role in cell signaling pathways that regulate cell growth and division. KRAS (Kirsten rat sarcoma viral oncogene homolog) is a type of oncogene, meaning it has the potential to cause normal cells to become cancerous when mutated or overactive.

 

Get a Free sample for the KRAS Inhibitors Market Report 

https://www.delveinsight.com/report-store/kras-inhibitors-market

 

KRAS Inhibitors Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

KRAS Inhibitors Epidemiology Segmentation:

The KRAS Inhibitors market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of KRAS Inhibitors

  • Prevalent Cases of KRAS Inhibitors by severity

  • Gender-specific Prevalence of KRAS Inhibitors

  • Diagnosed Cases of Episodic and Chronic KRAS Inhibitors

 

Download the report to understand which factors are driving KRAS Inhibitors epidemiology trends @ KRAS Inhibitors Epidemiology Forecast

 

KRAS Inhibitors Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the KRAS Inhibitors market or expected to get launched during the study period. The analysis covers KRAS Inhibitors market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the KRAS Inhibitors Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

KRAS Inhibitors Therapies and Key Companies

  • JDQ443: Novartis

  • Avutometinib: Verastem Oncology

  • BI 1701963: Boehringer Ingelheim

  • GDC-6036: Roche

  • LY353798: Eli Lilly

  • RMC-4630: Revolution Medicines

 

Discover more about therapies set to grab major KRAS Inhibitors market share @ KRAS Inhibitors Treatment Market

 

KRAS Inhibitors Market Strengths

  • Combining KRAS-targeted therapies with other treatment modalities, such as immunotherapies or traditional chemotherapy, holds promise for improving treatment outcomes. The potential for combination therapies creates additional market opportunities and enhances the overall market strength of KRAS mutations.

 

KRAS Inhibitors Market Opportunities

  • To enhance the effectiveness of KRASG12C inhibitors in NSCLC, it is crucial to integrate them into the first-line standard of care(SOC). Nevertheless, the currently available agents have encountered difficulties due to toxic side effects when combined with anti-PD-(L)1 therapy.

 

Scope of the KRAS Inhibitors Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key KRAS Inhibitors Companies: Novartis, Verastem Oncology, Boehringer Ingelheim, Roche, Eli Lilly, Revolution Medicines, and others

  • Key KRAS Inhibitors Therapies: JDQ443, Avutometinib, BI 1701963, GDC-6036, LY353798, RMC-4630, and others

  • KRAS Inhibitors Therapeutic Assessment: KRAS Inhibitors current marketed and KRAS Inhibitors emerging therapies

  • KRAS Inhibitors Market Dynamics: KRAS Inhibitors market drivers and KRAS Inhibitors market barriers 

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • KRAS Inhibitors Unmet Needs, KOL’s views, Analyst’s views, KRAS Inhibitors Market Access and Reimbursement 

 

To know more about KRAS Inhibitors companies working in the treatment market, visit @ KRAS Inhibitors Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. KRAS Inhibitors Market Report Introduction

2. Executive Summary for KRAS Inhibitors

3. SWOT analysis of KRAS Inhibitors

4. KRAS Inhibitors Patient Share (%) Overview at a Glance

5. KRAS Inhibitors Market Overview at a Glance

6. KRAS Inhibitors Disease Background and Overview

7. KRAS Inhibitors Epidemiology and Patient Population

8. Country-Specific Patient Population of KRAS Inhibitors 

9. KRAS Inhibitors Current Treatment and Medical Practices

10. KRAS Inhibitors Unmet Needs

11. KRAS Inhibitors Emerging Therapies

12. KRAS Inhibitors Market Outlook

13. Country-Wise KRAS Inhibitors Market Analysis (2020–2034)

14. KRAS Inhibitors Market Access and Reimbursement of Therapies

15. KRAS Inhibitors Market Drivers

16. KRAS Inhibitors Market Barriers

17.  KRAS Inhibitors Appendix

18. KRAS Inhibitors Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: KRAS Inhibitors Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2023-2032), Analyzes DelveInsight | Novartis, Verastem Oncology, Boehringer Ingelheim, Roche, Eli Lilly

Ace Therapeutics Unveils Gene Therapy Development Services to Fuel Glaucoma Research

Ace Therapeutics announced the unveiling of its gene therapy development services to advance glaucoma research.

To advance glaucoma research, Ace Therapeutics, an integrated biotechnology company with a broad research scope and comprehensive services, has announced the unveiling of its gene therapy development services. The company’s innovative gene therapy approach holds promise in providing a new, effective treatment option for individuals suffering from this eye disease that damages the optic nerve.

Glaucoma is a leading cause of irreversible blindness worldwide, and currently available treatments only offer temporary relief of symptoms. Studies have found the main risk factor for glaucoma is high IOP, primarily due to RGC injury and death. For this reason, Ace Therapeutics offers glaucoma gene therapy development services, targeting IOP and RGC-associated candidate genes, as well as many other related genes and pathways. By delivering therapeutic nucleic acids directly to the affected cells, the company’s gene therapy has the potential to halt the progression of glaucoma and preserve vision for patients.

Considering the great potential of stem cells as a possible therapy for glaucoma, the expert team at Ace Therapeutics can provide specialized services in glaucoma drug development, offer the opportunity to develop drugs for glaucoma using stem cell technology and stem cell-based therapies to restore vision loss due to glaucoma. In addition, the company also utilizes siRNA-based gene silencing strategies to treat glaucoma, providing researchers with development services to study the composition and mechanisms of siRNA drugs, offering solutions to the fundamental challenges faced during development.

“We are excited to collaborate with worldwide researchers to develop a more effective treatment for glaucoma using our gene therapy expertise and technologies,” said the senior scientist at Ace Therapeutics. “We can provide genomic analysis or directly select appropriate genes from candidate genes that are genetically linked to glaucoma to those involved in the relevant pathway. Also, we can develop gene delivery systems for glaucoma gene therapy to ensure the transfer of nucleic acid drugs to target cells and to advance the translational application of gene therapy.”

About Ace Therapeutics

Ace Therapeutics Glaucoma is an innovative ophthalmic disease research company that offers a wide range of services in basic research, drug development and preclinical studies, delivering innovative and high-quality solutions to global clients. Ace Therapeutics’ mission is to be a leader in the field of glaucoma research, providing unique drug development, and preclinical research solutions to advance researchers’ project development.

Media Contact
Company Name: Ace Therapeutics
Contact Person: Daisy Mostert
Email: Send Email
Country: United States
Website: https://www.acetherapeutics.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Ace Therapeutics Unveils Gene Therapy Development Services to Fuel Glaucoma Research

LASUCO: From Leading Agriculture Corporation To Asia’s top Best Under Billion By Forbes

“”We are committed to making the world a better place and nurturing the dreams of future generations,” states Tan Le Van, Chairman of LASUCO.”

Lam Son Town, Tho Xuan District, Thanh Hoa Province, Vietnam – May 13, 2024 – Lam Son Sugar Cane Joint Stock Corporation (LASUCO), under the leadership of Chairman Tan Le Van, has been honored as one of Forbes’ Asia’s Top Best Under A Billion companies. Celebrating over four decades of excellence, LASUCO is committed to sustainable, high-value added agricultural products and innovative, eco-friendly practices.

LASUCO’s story

Celebrating over 44 years of innovation and leadership in intensive agriculture, LASUCO has evolved from a medium-sized state-owned enterprise into Vietnam’s premier  agricultural group. With a focused vision on specialized intensive agriculture aimed at both domestic and international markets, LASUCO continues to set benchmarks in the industry. 

Brand identity

Adhering to the mantra “Everything is nature,” LASUCO encapsulates its commitment to eco-friendly, high-value added intensive agriculture. All its products, including a diverse range of sugars, vegetables, rice, and beverages like cane juice, herbal teas, drinks, and rice milk, originate from natural and safe sources. LASUCO’s comprehensive portfolio extends into farm and forest products, cattle feed, food processing, transport services, mechanics, material supply, and trade businesses.

LASUCO’s vision:

LASUCO aspires to lead the brand landscape in the intensive agriculture sector, focusing on a supply chain of clean, green agricultural products and nutrient-rich foods derived from nature. 

LASUCO’s mission:

LASUCO’s mission is global leadership in intensive agriculture, emphasizing nutritious, naturally sourced food products. LASUCO is dedicated to providing high-quality, eco-friendly products that promote human health. Its goal extends beyond commerce, aiming to enhance awareness and education about sustainable practices across diverse cultures and regions where LASUCO operates. “We are committed to making the world a better place and nurturing the dreams of future generations,” states Tan Le Van, Chairman of LASUCO. 

LASUCO’s heritage:

Throughout its history, LASUCO has cemented its reputation with prestigious international certifications such as The Quality Management System Certification ISO 9001: 2008, FSSC 22000, FDA approval, Certificate of Occupational Health Safety Management OHSAS 18001, and HALAL certification, among others. Recognized as one of Asia’s Best Under A Billion by Forbes and the Top 100 Vietnamese featured corporations on Alibaba, LASUCO remains at the forefront of technological advancement in agriculture. 

LASUCO’s values:

LASUCO’s operating principles are anchored in the value chain:

Morality  –  Respect

Comprehensiveness  – The best

Nature – High value

Creativity –  Innovation

Cooperation –  Effectiveness 

LASUCO’s purpose & contribution:

LASUCO aims to create innovative programs that connect people to new places and better opportunities, overcoming challenges through creativity and focused research. “Our dedication is towards building LASUCO into a sustainable agricultural economic group, enhancing our core industries, and developing a sustainable value chain that significantly improves the livelihoods and working conditions of our workers,” affirms Chairman Tan Le Van. 

Environmental Commitment

Being environmentally friendly is a long-term commitment of LASUCO to the community and a cornerstone of its sustainable development strategy.

Media Contact
Company Name: Lam Son Sugar Cane Joint Stock Corporation (LASUCO GROUP)
Contact Person: Jame Tran
Email: Send Email
Phone: +84904506783
Address:Lam Son Town, Tho Xuan District
City: Thanh Hoa
Country: Vietnam
Website: https://lasuco.vn/en/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: LASUCO: From Leading Agriculture Corporation To Asia\’s top Best Under Billion By Forbes

Forsentek Co., Limited Introduces Miniature Load Cell, 3-Axis Load Cell and Rotary Torque Sensor For Precision Measurements

Forsentek Co., Limited is introducing their vanguard offerings to the precision measurement industry with the debut of their Miniature Load Cell, 3-Axis Load Cell, and Rotary Torque Sensor.

In an industrial era where precision and accuracy are of paramount importance, Forsentek Co., Limited, a leading manufacturer and innovator in measurement sensor technology, has announced the advent of their latest, cutting-edge products: the Miniature Load Cell, the 3-Axis Load Cell, and the Rotary Torque Sensor. These advanced tools, designed for the meticulous demands of the modern world, underscore the commitment of Forsentek to facilitate a more efficient, accurate, and refined measurement solutions landscape for its global clientele.

miniature_3-axis_load_cell

The launch of the Miniature Load Cell represents a meaningful evolution in load cell technology. As smaller devices grow in importance in various industries, from automotive to consumer electronics, the need for precise measurements in compact constraints becomes crucial. This new type of load cell, designed with both compactness and high precision in mind, elegantly addresses this need. It promises exceptional reliability and accuracy, even under challenging conditions, ensuring that size no longer compromises measurement precision.

The revolutionary 3-Axis Load Cell has also been announced, offering a remarkable solution for multi-directional force measurement. Its ability to read forces in three different directions concurrently could transform how industries such as robotics, automotive, and biomechanics conduct force analysis. The combination of meticulous design, precision, and robust build enables more comprehensive and detailed capture of information in real-time, illuminating previously unseen aspects of force interactions.

micro_load_cell

Moreover, Forsentek is pushing the boundaries of torque measurement technology with their state-of-the-art Rotary Torque Sensor. This innovative product provides precise, accurate measurement of torque in rotating systems, essential for sectors that require accurate control and optimization of their processes, such as automotive testing, industrial automation, and energy systems.

Forsentek’s breakthroughs are hallmarks of a company at the frontier of sensor technology. They embody the spirit of continual innovation that has positioned Forsentek as a global leader in measurement solutions. It’s not just about creating sensor products for Forsentek; it’s about architecting the foundations of precision in countless industries and applications around the world.

About Forsentek Co., Limited

Located in Shenzhen, China, Forsentek Co., Limited is a globally recognized firm specializing in the manufacturing of high-quality sensor products. Their offerings include load cells, force sensors, and torque sensors, consistently setting industry benchmarks for quality and performance.

Media Contact
Company Name: Forsentek Co., Limited
Contact Person: Tarik Lu
Email: Send Email
Phone: +86 755 84536383
City: Shenzhen
Country: China
Website: http://www.forsentek.com

LASUCO’s Kanpe Red – Vietnamese Canned Sugarcane Juice Now Available In US Market

“The first batches of Vietnamese canned sugarcane juice made by Lam Son Sugar JSC(Lasuco), namely Kanpe Red, have recently hit the shelves of convenience stores and supermarkets in the coastal city of Miami in Florida of the US.”

Lam Son Town, Tho Xuan District, Thanh Hoa Province, Vietnam – May 13, 2024 – Lam Son Sugar Cane Joint Stock Corporation (LASUCO), a leader in Vietnam’s agricultural industry, is excited to announce that Kanpe Red, their premium canned sugarcane juice, is now available for purchase in Miami, Florida.

Sporting the vibrant Vietnamese national flag on each can, this new offering is introduced in partnership Between Lasuco with Henri R. Chaumin, a distinguished  United state of America businessman, ensuring a broad reach within various retail outlets including supermarkets and convenience stores. 

Kanpe Red stands out in the crowded beverage market due to its exceptional quality, having achieved certification from the US Food and Drug Administration (FDA). This certification underscores the drink’s adherence to the highest standards of quality and safety, attributes that are already winning over consumers in Miami since its introduction earlier this year. 

The drink’s unique selling point is its composition—99% pure sugarcane juice enhanced with a hint of kumquat flavor, offering a refreshing taste unlike any other in the market. This not only caters to health-conscious consumers looking for natural beverage options but also guarantees freshness and quality, maintaining its best taste for up to one year. 

Henri R. Chaumin, Chairman of Mega 4’s Bottling Company, shared insights into the competitive landscape, noting that another brand offers a product comprising only 32% sugarcane juice, with the remainder being water and added sugars. This stark contrast highlights the superior quality of Kanpe Red, setting a new standard for authenticity and taste in the sugarcane juice market. 

As part of a strategic expansion plan, Chaumin and Lasuco expressed their intention to distribute Kanpe Red across the United States, starting with densely Latin American populated coastal areas, and eventually reaching all 52 states. This approach not only taps into a demographic with an existing appreciation for sugarcane beverages but also broadens the potential consumer base. 

The expansion hopes are supported by positive regulatory conditions. According to Do Ngoc Hung, a Vietnamese Trade Counselor in the US, sugarcane juice products like Kanpe Red have favorable export prospects. They are not listed among items requiring pest risk-related inspections, facilitating smoother entry into the US market. 

Chaumin and LASUCO is optimistic about the future of Kanpe Red in the US, aiming for the drink to not only find a place in American homes but also to solidify the presence of the Vietnamese brand overseas. “We believe that Kanpe Red will become a household name, showcasing the best of Vietnamese agriculture and contributing to a more diverse American beverage market,” said Chaumin. 

With LASUCO’s commitment to quality and Chaumin’s strategic distribution plans, Kanpe Red is set to become a significant player in the US beverage industry, providing consumers with a healthy, flavorful alternative that pays homage to its Vietnamese roots, affirms Trung Tran Xuan, Import- Export Vice Director of LASUCO.

Media Contact
Company Name: Lam Son Sugar Cane Joint Stock Corporation (LASUCO GROUP)
Contact Person: Jame Tran
Email: Send Email
Phone: +84904506783
Address:Lam Son Town, Tho Xuan District
City: Thanh Hoa
Country: Vietnam
Website: https://lasuco.vn/en/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: LASUCO\’s Kanpe Red – Vietnamese Canned Sugarcane Juice Now Available In US Market